Main Category: Obesity / Weight Loss / Fitness
Also Included In: Diabetes
Article Date: 20 May 2011 ? 5:00 PDT
email to a friend ? printer friendly ? opinions ?
<!? rate article
Patient / Public:
2 (1 votes)
Healthcare Prof:
AMRI (NASDAQ: AMRI) will present results from a Phase 1 clinical study with its Melanin Concentrating Hormone Receptor 1 (MCH1) antagonist, ALB-127158(a), at the 18th European Congress on Obesity (ECO2011, May 25-28, 2011, Istanbul, Turkey).
The results will be presented by Dr. Nicholas Moore, director of development and pharmacology as a Hot Topic Poster (poster HTP.022) during the afternoon session on Thursday, May 26, 2011 and in a subsequent oral session on Friday, May 27, 2011 at 5:45 p.m.
The presentation will provide data from both a single ascending dose study and a multiple ascending dose study designed to assess safety, tolerability and pharmacokinetics. The multiple ascending dose study included evaluations designed to indicate pharmacodynamic effects of the compound.
The clinical study was initiated in July 2010 following promising preclinical results which showed high levels of MCH1 receptor occupancy leading to a sustained, dose-related reduction in food intake in dietary-induced obese mice.
?We are pleased to be sharing our Phase I results for this promising new compound,? said Dr. Bruce Sargent, Ph.D., senior vice president of drug discovery. ?MCH1 receptor antagonism has been long recognized as a potential approach to treatment of obesity. We are proud to be one of the first companies to progress a compound through Phase I clinical trial.?
Source:
Albany Molecular Research, Inc. (AMRI)
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.
? Follow us on Twitter
? Obesity / Weight Loss / Fitness headlines
? email to a friend
? printer friendly version
? weekly newsletter
? personalize your news
? back to top
Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd ? 2004-2011 All rights reserved.
Article source: http://www.medicalnewstoday.com/releases/226031.php
the tree of life isc kia soul infamous pms zach galifianakis fable 3 pc
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.